Location: Home >> Editorial Board

Editor Profile

Antonio Ruggiero

Section Editor-in-Chief

Catholic University of Rome, Italy

Email:

Antonio.Ruggiero@unicatt.it

Antonio Ruggiero

Catholic University of Rome, Department of Pediatrics, Division of Pediatric Oncology, Head of the Pediatric Hematology and Experimental Therapies Unit, Italy

Section: Clinical Pharmacology

Specialty Area

pediatric clinical trials, clinical pharmacology of antineoplastic drugs, pain therapy and pediatric drugs

Editor introduction

Experience on the conduction of phase I-II trials with a special focus on the clinical development of new antineoplastic agents. 
 
Participation in clinical trials:
 
1996: “Cytotoxicity of  new cisplatin’ analogues on neuroblastoma cell lines”.  Italian Ministry of University 
1997: “Preclinical studies on antineoplastic efficacy of new platinum compounds in neuroblastoma”. Italian Ministry of University
2000: “Case-control study on leukemias, neoplasms and growth delay in children exposed to magnetic fields”. National Institute of Prevention and Safety (ISPELS)
2001: “Molecular features of  malignancy and innovative therapies in pediatric solid tumors”. Italian Ministry of Health 
2001: “Phase II trial with Temozolomide in children and young adults with brain tumor refractory to the first- and second-line treatment” 
2001: “Preclinical studies on the combined therapy 125-I-MIBG and cisplatin in neuroblastoma”. Italian Ministry of University
2002: “Phase II trial of Irinotecan in pediatric patients with soft tissue tumors”. Catholic University of Rome/University of Padua 
2006: “Phase I-II trial with Temozolomide and oral Etoposide in children with relapsed or recurrent medulloblastoma/PNET and high-grade glioma” 
2006: “Antitumoral activity of new atypical retinoids in medulloblastoma”
2007: “Phase II trial with gemcitabine and oxaliplatin in pediatric recurrent or refractory solid tumours”
2008: “Phase II trial with transdermal Buprenorphine in children with pain cancer”
2009: “Phase II trial, single arm, temozolomide and topotecan in refractory and recurrent neuroblastoma and in other solid tumours”
2009: “Phase II trial with intranasal midazolam by MAD (Mucosal Atomizer Device) for procedural pain”
2009:  “H1N1v vaccination in children with cancer”
2010:  “Patient Controlled Analgesia (PCA) for cancer pain in childhood” 
2011:  “Phase II pharmacokinetic study to assess the age-dependency in the  clearance of doxorubicin in paediatric patients with solid tumours and leukaemia (EPOC-MS-001-Doxo)
2011: “A phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma” (BO25041C/ITCC019/HGG-01).
2011: “Liquoral neurotoxicity markers in children with acute lymphoblastic leukemia”
2012: “Neural effects of topical Nerve Growth Factor (NGF) in patients with visual deficits due to optic gliomas”
2012: “Predictive value of biomarkers of sepsis in children with febrile neutropenia”
2012: “A phase I/II study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway and adult patients with recurrent or refractory medulloblastoma”
2013: “Neurocognitive assessment in children with brain tumors”
2014: “Diagnostic accuracy and Assessment of Chemotherapy Response Using FDG-PET in Pediatric Ewing sarcoma“
2015: “Sviluppo di uno score per l’identificazione di bambini sottoposti a chemioterapia ad alto rischio di CINV”  (Fondi Ateneo linea D.1 per progetti di ricerca)
2016: “An early-phase, multicenter, open-label study of the safety and pharmacokinetics of Anti-PD-L1 antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors” (Roche)
2016: “A phase I/II, multicenter, open-label. Dose-escalation study of the safety and pharmacokinetics of cobimetinib in pediatric and young adult patients with previously treated solid tumors”. (Roche)
2016: “A phase 1/2, multicenter, open-label. dosefinding, study to assess the safety, tolerability, and preliminary efficacy of weekly nab - Paclitaxel in pediatric patients with recurrent or refractory solid tumors”. (Celgene)

Selected Scholarly Contributions

  • 1.
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.

Copyright © 2019 Hapres Co., Ltd. Privacy Policy | Terms and Conditions